Compare SRI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | LYEL |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 213.4M |
| IPO Year | 1997 | 2021 |
| Metric | SRI | LYEL |
|---|---|---|
| Price | $6.22 | $7.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.88 |
| AVG Volume (30 Days) | ★ 155.1K | 139.5K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $824,444,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.46 | N/A |
| 52 Week Low | $4.60 | $8.21 |
| 52 Week High | $9.71 | $45.00 |
| Indicator | SRI | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 29.33 | 19.53 |
| Support Level | $6.14 | N/A |
| Resistance Level | $7.51 | $15.38 |
| Average True Range (ATR) | 0.22 | 0.51 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 4.40 | 1.97 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Geographically, the company generates key revenue from the United States.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.